129 related articles for article (PubMed ID: 38182487)
1. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
3. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R
Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609
[TBL] [Abstract][Full Text] [Related]
5. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS; Alkallas R; Carroll SB; Caressi C; Zakria D; Patel NM; Trembath DG; Ezzell JA; Pegna GJ; Googe PB; Galeotti JP; Ayvali F; Collichio FA; Lee CB; Ollila DW; Gulley ML; Johnson DB; Kim KB; Watson IR; Moschos SJ
BMC Cancer; 2022 Jan; 22(1):38. PubMed ID: 34986841
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
8. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
10. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
15. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
17. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
18. Germline and somatic DNA repair gene alterations in prostate cancer.
Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
[TBL] [Abstract][Full Text] [Related]
19. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Ting WC; Chen LM; Huang LC; Liu CC; Chen CW; Hsieh CJ; Yang WH; Chang TY; Lee HZ; Bao BY
Ann Surg Oncol; 2010 Jan; 17(1):312-22. PubMed ID: 19777185
[TBL] [Abstract][Full Text] [Related]
20. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.
Schell MJ; Yang M; Teer JK; Lo FY; Madan A; Coppola D; Monteiro AN; Nebozhyn MV; Yue B; Loboda A; Bien-Willner GA; Greenawalt DM; Yeatman TJ
Nat Commun; 2016 Jun; 7():11743. PubMed ID: 27302369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
